A Study of NT-175 in Adult Subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Trial Identifier: NT-175-201
Sponsor: AstraZeneca
Collaborator:
AstraZeneca
Start Date: July 2023
Primary Completion Date: September 2028
Study Completion Date: August 2039
Condition: Breast Cancer; Colorectal Cancer; Cancer - Other; Lung Cancer; Ovarian Cancer; Pancreatic Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States, California Duarte, California, United States, 91010
United States, California Los Angeles, California, United States, 90095
United States, California Newport Beach, California, United States, 92663
United States, Massachusetts Boston, Massachusetts, United States, 02215
United States, New Jersey New Brunswick, New Jersey, United States, 09803
United States, Oregon Portland, Oregon, United States, 97225
United States, Tennessee Nashville, Tennessee, United States, 37203
United States, Texas Dallas, Texas, United States, 75246
United States, Texas Houston, Texas, United States, 77030